Treanda (bendamustine, SDX-105)
Updated: Nov 14, 2009
| Brand Name: | Treanda |
| Generic Name: | bendamustine |
| Code Name: | SDX-105 |
| Company: | Cephalon Oncology |
| FDA Clinical Phase: | 1/2 |
Description:
Treanda (news articles) is a drug that is used to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL) . It is also being studied in the treatment of other types of cancer. Treanda is a type of purine analog/alkylator hybrid drug, which may damage the DNA in cancer cells and kill them.
Clinical Trials:
For a list of clinical trials studying Treanada for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for Treanda: http://www.treanda.com/
Source: NCI Cancer Glossary, Treanda, http://www.cancer.gov/dictionary/?searchTxt=treanda (as of November 14, 2009)
Related Articles:
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Getting To Know: Tiragolumab
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- Number And Type Of Stem Cell Transplants Carried Out Each Year For Multiple Myeloma Vary Markedly Across U.S. Cancer Centers
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients